ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 42 of 67
Up
УЖМБС 2020, 5(3): 312–318
https://doi.org/10.26693/jmbs05.03.312
Social medicine and organization of health care

Clinical and Economic Analysis of the State of Pharmaceutical Provision of Patients with Gastroesophageal Reflux Disease on the Background of Chronic Gastric Disease

Matushchak M. R., Horoshko O. M., Zakharchuk O. I., Ezhned M. А., Sakhatska I. М., Kostyshyn L. V., Mykhailiuk N. V., Drachuk V. M.
Abstract

Heartburn is one of the main symptoms of a disease associated with gastric ulceration and the risk of developing other esophageal lesions that lead to poor quality of life. Therefore, the study of this problem in the aspect of treatment and prevention actual relevant in modern gastroenterology. The recent studies found out that approximately 10% of adults and almost 50% of pregnant women experience heartburn which is the main symptom of gastroesophageal reflux disease daily, 30% have it at least once a week, 60%have it at least once a month. The number of people suffering from heartburn ranges from 30 to 60% of the population, which is equally common in men and women. Long-term studies of scientists have shown that the number of people who experience heartburn at least once a week has doubled in 10 years. The purpose of the work was to improve the quality of pharmacotherapy of patients with gastroesophageal reflux disease by conducting the pharmacoeconomic analysis of the proton pump inhibitors and propulsants use with improving the order of formation of the local formulary of treatment and preventive care establishments. Material and methods. The study included the analysis of 123 medical records of patients with gastroesophageal reflux disease on the background of chronic gastritis and medical prescription sheets of medical institutions in Chernivtsi. Results and discussion. The analysis was performed on the basis of in-patients' medical records and medical records of medical institutions, according to which the most used drugs of the group of antisecretory agents and peristalsis stimulants were identified. For pharmacoeconomic studies the index of treatment effectiveness was determined. According to the results, the combination "Nolpaza+Itomed" was 87%, and the "cost-effectiveness" index was 128.40 UAH; "Ezolong+Itomed" – 88%, the "cost-effectiveness" index was 145.60 UAH. The "Ezolong+Itomed" combination has the most potent effect on heartburn elimination and has a significantly higher efficacy compared to the other studied combinations, while almost identical clinical efficacy rates are observed compared to “Nolpaza+Itomed” combination. According to the results of pharmacoeconomic analyzes of “cost minimization” and “cost-effectiveness”, the most rational from the economic point of view is the “Nolpaza+Itomed” combination, since the treatment cost is 30.58 UAH per day, and the effectiveness and combination is ahead of other pharmacotherapy schemes. Conclusion. The obtained data are promising for further research and revision of local formularies of treatment and preventive care establishments regarding the inclusion of medicines from the group of antisecretory agents and propulsants.

Keywords: gastroesophageal reflux disease, pharmacotherapy, pharmacoeconomic analysis

Full text: PDF (Ukr) 403K

References
  1. Babak OYa. HERKh. Vid teorii do praktyky [GERD. From theory to practice]. Suchasna hastroenterolohiia. 2014; 4(78): 38-44. [Ukrainian]
  2. Hastroezofahealnaia refliuksnaia bolezn [Gastroesophageal reflux disease]. Uchebnoe posobye. Ed by YV Maev. M: HEOTAR-Medya; 2019. 80 s. [Russian]
  3. Mahlovana H. Vplyv fizychnoi aktyvnosti ta sposobu zhyttia na poshyrenist hastroezofahealnoi refliuksnoi khvoroby u studentiv [The influence of physical activity and lifestyle on the prevalence of gastroesophageal reflux disease in students]. Sportyvna nauka Ukrainy. 2015; 1(65): 36-40. [Ukrainian]
  4. Yakhnytska M. Osoblyvosti klinichnoho perebihu hastroezofahealnoi refliuksnoi khvoroby u lvivskomu rehioni [Features of clinical course of gastroesophageal reflux disease in Lviv region]. Zdobutky klinichnoi i eksperymentalnoi medytsyny. 2019; 1: 195-201. [Ukrainian]
  5. Vdovychenko VI, Ostrohliad AV, Sverdan YaP. "Pechiia vykhidnoho dnia": poshyrenist, faktory ryzyku, profilaktyka [Weekend Heartburn: Prevalence, Risk Factors, Prevention]. Suchasna hastroenterolohiia. 2012; 1(63): 88-93. [Ukrainian]
  6. Mahlovana HM, Bychkov MA, Kovalchuk HI. Funktsionalna pechiia ta hastroezofahealna refliuksna khvoroba u studentiv u period zminenoho psykhoemotsiinoho stanu [Functional heartburn and gastroesophageal reflux disease in students in the period of altered psycho-emotional state]. Suchasna hastroenterolohiia. 2011; 6: 29-31. [Ukrainian]
  7. Chernobrovyi VM, Melashchenko SH. Suchasni aspekty diahnostyky i farmakoterapii hastroezofahealnoi refliuksnoi khvoroby [Current aspects of diagnosis and pharmacotherapy of gastroesophageal reflux disease]. Suchasna hastroenterolohiia. 2013; 3(71): 92-9. [Ukrainian]
  8. Hutsalenko OO. Optymizatsiia likuvannia duodenohastralnoho refliuksu u khvorykh na khronichnyi hastryt [Optimization of treatment of duodenogastric reflux in patients with chronic gastritis]. Gastroenterologìa. 2019; 53(3): 153-61. [Ukrainian] https://doi.org/10.22141/2308-2097.53.3.2019.181467
  9. Plotnykova EYu, Volohzhanyna LH, Yhumnova OA, Kolmohorova TO. Pryntsypu lechenyia khronycheskoho ezofahyta razlychnoi etyolohyy [Principles of treatment of chronic esophagitis of various etiologies]. Medytsynskyi sovet. 2017; 20: 124-30. [Russian] https://doi.org/10.21518/2079-701X-2017-20-124-130
  10. Herasymova OO, Krykun VV. Analiz asortymentu ta dostupnosti stymuliatoriv perystaltyky na farmatsevtychnomu rynku Ukrainy [Analysis of the range and availability of peristalsis stimulants in the pharmaceutical market of Ukraine]. Klinichna farmatsiia. 2019; 23(2): 54-9. [Ukrainian] https://doi.org/10.24959/cphj.19.1492
  11. Gubergrits NB, Belaeva NV, Klochkov OYe, Suprun OO, Fomenko PG. Mistse inhibitoriv protonnoi pompy u likuvanni khronichnoho pankreatytu. Ohliad ta vlasni sposterezhennia [Place of proton pump inhibitors in the treatment of chronic pancreatitis. Review and own observations]. Suchasna hastroenterolohiia. 2018; 2: 85-94. [Ukrainian]
  12. Zhuravlova LV, Filonenko MV. Hastroezofahealna refliuksna khvoroba v osib z metabolichnym syndromom: osoblyvosti perebihu ta suchasni pidkhody do likuvannia [Gastroesophageal reflux disease in persons with metabolic syndrome: features of the course and current approaches to treatment]. Suchasna hastroenterolohiia. 2018;  4(102): 94-9. [Ukrainian]
  13. Palii IH, Zaika SV, Kolisnyk SP. Rol innovatsiinoi formy pantoprazolu v likuvanni khvorykh na NPZP hastropatiiu [The role of the innovative form of pantoprazole in the treatment of patients with NSAIDs of gastropathy]. Suchasna hastroenterolohiia. 2012; 1(63): 88-93. [Ukrainian]
  14. Palii IH, Zaika SV, Kolisnyk SP, Vavrynchuk VV, Salabai IO. Rol innovatsiinoi formy pantoprazolu v likuvanni khvorykh na NPZP-hastropatiiu [The role of the innovative form of pantoprazole in the treatment of patients with NSAIDs-gastropathy]. Suchasna hastroenterolohiia. 2012; 1: 88-93. [Ukrainian]
  15. Yang YJ, Bang CS, Baik GH, Park TY, Shin SP, Suk KT, et al. Prokinetics for the treatment of functional dyspepsia: Bayesian network meta-analysis. BMC Gastroenterol. 2017 Jun 26; 17(1): 83. [Korea] https://www.ncbi.nlm.nih.gov/pubmed/28651565. https://www.ncbi.nlm.nih.gov/pmc/articles/5485548.https://doi.org/10.1186/s12876-017-0639-0
  16. Palii IH, Zaika SV, Prymak OS. Kyslotozalezhni zakhvoriuvannia u khvorykh na metabolichnyi syndrom: nevyrisheni problemy i suchasni mozhlyvosti likuvannia [Acid-dependent diseases in patients with metabolic syndrome: unresolved problems and current treatment options]. Suchasna hastroenterolohiia. 2014; 1: 83-92. [Ukrainian]
  17. Makhov MA, Yvashev MN. Itomed v klynycheskoi praktyke [Itomed in clinical practice]. Mezhdunarodnyi zhurnal eksperymentalnoho obrazovanyia. 2016; 10(2): 232-3. [Russian]
  18. Shcherbynyna MB. Itomed: ratsyonalnoe lechenye dyskynezyi zheludochno-kyshechnoho trakta [Itomed: a rational treatment of dyskinesia of the gastrointestinal tract]. Polyklynyka. 2012; 4: 52-54. [Russian]